Recombinant human interleukin-15
As of the edition of 20 October 2026, Recombinant human interleukin-15 is a drug: stopped in 2021; acts on IL15RA.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Stopped, 2021
- Kind
- Unknown
- Registered trials
- 11, 2 stopped early
- Disease areas
- Cancer; Blood and lymph; Immune system; Pregnancy and women's health; Urinary and reproductive; Lungs and airways
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| IL15RA | Interleukin-15 receptor subunit alpha | Q13261 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 10 | 8 | 1 | 1 |
| Phase 2 | 1 | 0 | 0 | 1 |
| All trials | 11 |